Methamphetamine (MA) is the most commonly used psychostimulant drug, the chronic abuse of which leads to neurodegenerative changes in the brain. The global use of MA is increasing, including in pregnant women. Since MA can cross both placental and haematoencephalic barriers and is also present in maternal milk, children of chronically abused mothers are exposed prenatally as well as postnatally. Women seem to be more vulnerable to some aspects of MA abuse than men. MA is thought to exert its effects among others via direct interactions with dopamine transporters (DATs) in the brain tissue. Sexual dimorphism of the DAT system could be a base of sex-dependent actions of MA observed in behavioural and neurochemical studies. Possible sex differences in the DATs of preadolescent offspring exposed to MA prenatally and/or postnatally have not yet been evaluated. We examined the striatal synaptosomal DATs (the activity and density of surface expressed DATs and total DAT expression) in preadolescent male and female Wistar rats (31-35-day old animals) exposed prenatally and/or postnatally to MA (daily 5 mg/kg, s.c. to mothers during pregnancy and lactation). To distinguish between specific and nonspecific effects of MA on DATs, we also evaluated the in vitro effects of lipophilic MA on the fluidity of striatal membranes isolated from preadolescent and young adult rats of both sexes. We observed similar changes in the DATs of preadolescent rats exposed prenatally or postnatally (MA-mediated drop in the reserve pool but no alterations in surface-expressed DATs). However, prenatal exposure evoked significant changes in males and postnatal exposure in females. A significant decrease in the activity of surface-expressed DATs was found only in postnatally exposed females sensitized to MA via prenatal exposure. MA applied in vitro increased the fluidity of striatal membranes of preadolescent female but not male rats. In summary, DATs of preadolescent males are more sensitive to prenatal MA exposure via changes in the reserve pool and those of preadolescent females to postnatal MA exposure via the same mechanism. The combination of prenatal and postnatal MA exposure increases the risk of dopaminergic deficits via alterations in the activity of surface-expressed DATs especially in preadolescent females. MA-mediated changes in DATs of preadolescent females could be still enhanced via nonspecific disordering actions of MA on striatal membranes.

Department of Normal Pathological and Clinical Physiology 3rd Faculty of Medicine Charles University Prague Prague Czech Republic

Institute of Computer Science The Czech Academy of Sciences Prague Czech Republic

National Institute of Mental Health Topolova 748 250 67 Klecany Czech Republic

Zobrazit více v PubMed

Brain Dev. 1986;8(4):390-6 PubMed

Biochemistry. 2001 Jul 24;40(29):8563-71 PubMed

Ann N Y Acad Sci. 2004 Oct;1025:602-11 PubMed

J Neurochem. 2010 Apr;113(1):27-41 PubMed

Obstet Gynecol. 2009 Jun;113(6):1285-91 PubMed

Neuroendocrinology. 2005;82(2):78-86 PubMed

Neurosci Biobehav Rev. 2003 Jan-Mar;27(1-2):3-18 PubMed

Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jan;30(1):82-8 PubMed

Brain Res Dev Brain Res. 1996 Jul 20;94(2):109-20 PubMed

Front Neuroendocrinol. 2008 Jan;29(1):36-47 PubMed

J Pharmacol Exp Ther. 2009 Apr;329(1):169-74 PubMed

J Neurosci. 1991 May;11(5):1325-33 PubMed

Physiol Behav. 2010 Mar 3;99(3):381-7 PubMed

Gen Comp Endocrinol. 2014 Feb 1;197:18-25 PubMed

Ann N Y Acad Sci. 1998 May 30;844:153-65 PubMed

Toxicol Appl Pharmacol. 2005 Dec 15;209(3):203-13 PubMed

Brain Res Dev Brain Res. 1990 May 1;53(2):222-9 PubMed

Neurotoxicol Teratol. 1996 Mar-Apr;18(2):199-215 PubMed

J Subst Abuse Treat. 2002 Sep;23(2):145-50 PubMed

Synapse. 2008 Oct;62(10):736-45 PubMed

Brain Res Dev Brain Res. 1997 Nov 12;103(2):155-62 PubMed

Brain Res. 1995 Sep 18;692(1-2):269-72 PubMed

Biochemistry. 2000 Aug 22;39(33):10309-18 PubMed

Neurochem Res. 2012 Mar;37(3):604-13 PubMed

Exp Gerontol. 2013 Mar;48(3):319-25 PubMed

Neuroscience. 2000;95(4):1061-70 PubMed

Dev Psychobiol. 2013 Apr;55(3):232-42 PubMed

Drug Alcohol Depend. 2014 Jun 1;139:138-44 PubMed

Int J Dev Neurosci. 2009 Oct;27(6):525-30 PubMed

Subst Abuse. 2014 Apr 28;8:25-33 PubMed

Nat Rev Neurosci. 2003 Jan;4(1):13-25 PubMed

Ann N Y Acad Sci. 2000 Sep;914:431-8 PubMed

J Neurochem. 2001 Sep;78(5):952-9 PubMed

Int J Mol Sci. 2014 Apr 08;15(4):5884-906 PubMed

J Neurosci. 2004 Mar 31;24(13):3436-43 PubMed

J Neurochem. 2014 May;129(3):495-508 PubMed

J Neuroendocrinol. 2005 Aug;17(8):509-17 PubMed

Neuroendocrinology. 1993 Jul;58(1):16-22 PubMed

Front Neurosci. 2015 May 27;9:178 PubMed

Brain Res Dev Brain Res. 1996 Jun 14;94(1):37-43 PubMed

Psychopharmacology (Berl). 2014 Apr;231(8):1581-99 PubMed

Physiol Res. 2009;58(5):741-50 PubMed

Brain Res Rev. 2009 May;60(2):379-407 PubMed

Int J Dev Neurosci. 2015 Apr;41:44-62 PubMed

Brain Res. 1996 Apr 1;714(1-2):95-103 PubMed

Neuropsychopharmacology. 2006 Jun;31(6):1193-202 PubMed

Arch Biochem Biophys. 1992 May 15;295(1):161-71 PubMed

Psychopharmacology (Berl). 1994 Apr;114(3):402-8 PubMed

Brain Res Dev Brain Res. 2001 Jul 23;129(1):73-9 PubMed

Indian J Biochem Biophys. 2013 Feb;50(1):32-9 PubMed

Neuroscience. 1988 Jun;25(3):857-87 PubMed

Biol Psychiatry. 2011 Nov 1;70(9):842-51 PubMed

J Neural Transm Gen Sect. 1993;93(1):67-70 PubMed

J Neuroendocrinol. 2007 Sep;19(9):682-90 PubMed

Synapse. 1993 Mar;13(3):241-50 PubMed

J Comp Neurol. 1992 Sep 8;323(2):299-304 PubMed

Physiol Rev. 2008 Jan;88(1):91-124 PubMed

Anal Biochem. 1976 May 7;72:248-54 PubMed

Brain Res. 2005 Feb 28;1035(2):188-95 PubMed

Neuropsychopharmacology. 2012 Feb;37(3):586-608 PubMed

J Pharmacol Exp Ther. 2010 Oct;335(1):207-12 PubMed

PLoS One. 2011 Jan 27;6(1):e16350 PubMed

Cell Death Dis. 2013 Oct 10;4:e850 PubMed

JAMA. 2000 May 3;283(17):2225-6 PubMed

J Neurochem. 1993 May;60(5):1876-83 PubMed